Rationale for NTRK Testing in Patients With Cancer

In this episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss the biologic rationale behind testing for NTRK fusions in patients with various solid tumors, along with clinical strategies for testing. Topics include:Differences between NTRK fusions vs gene mutationsFrequency of NTRK fusions by age and tumor typeWhen to test patients for NTRK fusions and interpreting reportsMethods of testing: multiplex gene testing, next-generation sequencing of DNA vs RNA, immunohistochemistry, and liquid biopsyPresenters:George D. Demetri, MDProfessor of MedicineHarvard Medical SchoolHarvard UniversityCo-Director, Ludwig Center at HarvardSenior Vice President for Experimental TherapeuticsDirector, Sarcoma CenterDana-Farber Cancer InstituteBoston, MassachusettsAlexander Drilon, MDChief, Early Drug DevelopmentAttending, ThoracicMemorial Sloan Kettering Cancer CenterNew York, New YorkLink to full program:https://bit.ly/2YFIPfrLink to slideset based on this podcast:https://bit.ly/3amgU6w  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.